NEW YORK (GenomeWeb News) – Expression Pathology and Flagship Biosciences today announced a service partnership to enable tissue translational biomarker development, validation, and application to support new drug development.
The new offering combines Expression's expertise in multiplex tissue proteomic assays using frozen formalin, paraffin-fixed tissues with Flagship's pathology expertise.
Based in Flagstaff, Ariz., Flagship provides digital pathology services. Expression is based in Gaithersburg, Md., and develops assays to measure functional tissue proteins.
Customers of both firms will now be able to "leverage expertise with tissue biomarkers to quickly develop quantitative evidence-based assays using the combined know how of mass spec tissue analysis and digital pathology," Flagship said in a statement.
Financial and other terms of the deal were not disclosed.